Products
Platform
Research
Market
Learn
Compare Aditya Birla Sun Life Pharma & Healthcare Fund vs UTI Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.31 | 2.25 |
NAV | ₹31.40 | ₹296.01 |
Fund Started | 20 Jun 2019 | 01 Aug 2005 |
Fund Size | ₹845.30 Cr | ₹1118.41 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
2.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.31
2.25
NAV
₹31.40
₹296.01
Fund Started
20 Jun 2019
01 Aug 2005
Fund Size
₹845.30 Cr
₹1118.41 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 30 days.
Returns
1 Year | -2.85% | 2.67% |
3 Year | 23.23% | 26.55% |
5 Year | 15.49% | 18.17% |
1 Year
-2.85%
2.67%
3 Year
23.23%
26.55%
5 Year
15.49%
18.17%
Holding Analysis
Equity | 97.86% | 99.35% |
Cash | 2.14% | 0.64% |
Equity
97.86%
99.35%
Cash
2.14%
0.64%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.96% |
Apollo Hospitals Enterprise Ltd. | 7.65% |
Cipla Ltd. | 7.09% |
Fortis Healthcare Ltd. | 5.15% |
Abbott India Ltd. | 4.82% |
Lupin Ltd. | 4.40% |
Torrent Pharmaceuticals Ltd. | 4.31% |
Ajanta Pharma Ltd. | 3.79% |
Ipca Laboratories Ltd. | 3.61% |
Anthem Biosciences Ltd. | 3.40% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.42% |
Cipla Ltd. | 5.68% |
Ajanta Pharma Ltd. | 5.38% |
Lupin Ltd. | 4.57% |
Dr. Reddy's Laboratories Ltd. | 4.06% |
Procter & Gamble Health Ltd. | 3.99% |
Fortis Healthcare Ltd. | 3.79% |
Glenmark Pharmaceuticals Ltd. | 3.78% |
Apollo Hospitals Enterprise Ltd. | 3.61% |
Alkem Laboratories Ltd. | 3.41% |
Fund Manager
Name | Dhaval Joshi | Kamal Gada |
Start Date | 21 Nov 2022 | 02 May 2022 |
Name
Dhaval Joshi
Kamal Gada
Start Date
21 Nov 2022
02 May 2022
About Fund
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 20 Jun 2019 | 01 Aug 2005 |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
20 Jun 2019
01 Aug 2005
